LRT tow attempt fails, further catenary damage and extended closure – CBC.caUS health officials on Friday approved a closely watched Alzheimer’s drug that modestly slows the brain-robbing disease, albeit with potential safety risks that patients and their doctors will have to carefully weigh. The U.S. Food and Drug Administration (FDA) has approved it for patients with Alzheimer’s disease, especially those with mild or early-stage disease. ‘I have quite serious doubts’Leqembi works by clearing up a sticky brain protein called amyloid, a hallmark of Alzheimer’s disease. LOOK | The pros and cons of Aduhelm: Debating the risks, benefits of a controversial Alzheimer’s drug There is debate over whether Canada should follow the US lead and approve a controversial Alzheimer’s drug despite concerns that Aducanumab is ineffective and could be harmful. Betsy Groves, 73, of Cambridge, Massachusetts, was diagnosed with Alzheimer’s disease in 2021.
